Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology.
暂无分享,去创建一个
L. Schwartz | Binsheng Zhao | M. Maitland | M. Gönen | G. Kelloff | C. Moskowitz | L. Dercle | G. Oxnard | S. Karovic | P. Hilden | Ying Tang | S. Adam | Dana E. Connors
[1] Robert Ford,et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.
[2] Lawrence H. Schwartz,et al. A Response Assessment Platform for Development and Validation of Imaging Biomarkers in Oncology , 2016, Tomography.
[3] L. Schwartz,et al. Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors. , 2016, JAMA oncology.
[4] W. Tsai,et al. Reproducibility of radiomics for deciphering tumor phenotype with imaging , 2016, Scientific Reports.
[5] M. Maitland,et al. Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling , 2016, Clinical and translational science.
[6] L. Schwartz,et al. Semiautomatic segmentation of liver metastases on volumetric CT images. , 2015, Medical physics.
[7] M. Burotto,et al. Pseudoprogression and Immune-Related Response in Solid Tumors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Wei Zhou,et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. , 2015, The Lancet. Oncology.
[9] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.
[10] J. Tabernero,et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. , 2014 .
[11] L. Schwartz,et al. Response phenotype as a predictive biomarker to guide treatment with targeted therapies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Binsheng Zhao,et al. Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals. , 2013, European journal of radiology.
[13] Yi-long Wu,et al. LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. , 2013 .
[14] L. Schwartz,et al. Segmentation of lung lesions on CT scans using watershed, active contours, and Markov random field. , 2013, Medical physics.
[15] E. Van Cutsem,et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] L. Schwartz,et al. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. , 2012, Journal of the National Cancer Institute.
[17] J Jack Lee,et al. Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] L. Sequist,et al. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Yan Sun,et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. , 2012, The Lancet. Oncology.
[20] G. Pond,et al. Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. , 2012, Journal of the National Cancer Institute.
[21] S. Bates,et al. Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth , 2012, Clinical Cancer Research.
[22] M. Maitland,et al. Clinical trials in the era of personalized oncology , 2011, CA: a cancer journal for clinicians.
[23] M. Maitland,et al. A time to keep and a time to cast away categories of tumor response. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Josep Tabernero,et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Michael L Maitland,et al. Volumes to Learn: Advancing Therapeutics with Innovative Computed Tomography Image Data Analysis , 2010, Clinical Cancer Research.
[26] C. Sternberg,et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Binsheng Zhao,et al. Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. , 2009, Radiology.
[28] Haesun Choi,et al. We should desist using RECIST, at least in GIST. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Joseph A DiMasi,et al. Economics of new oncology drug development. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Van V. Brantner,et al. Estimating the cost of new drug development: is it really 802 million dollars? , 2006, Health affairs.
[31] Wendy Brown,et al. Variability in response assessment in solid tumors: effect of number of lesions chosen for measurement. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] E. Van Cutsem,et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. , 2014, European journal of cancer.
[33] J. Reeves,et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.
[34] L. Tanoue,et al. Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes , 2012 .